Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recent Tech Transfer Deals (05/2009)

This article was originally published in Start Up

Executive Summary

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

You may also be interested in...



What Is Behind China's 'Zero-COVID'? Money-Making Machines And Business Interest Chains

One well-connected individual registered as many as 35 nucleic testing firms within just a few months, all of which are strategically located in the Chinese cities that have seen some of the worst COVID-19 flareups. Meanwhile, regulators have halted the IPOs of 13 companies.

Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests

UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC091796

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel